Safety and pharmacokinetics of plasma-derived mannose-binding lectin (MBL) substitution in children with chemotherapy-induced neutropaenia

Mannose-binding lectin (MBL)-deficient children with cancer may benefit from substitution of the innate immune protein MBL during chemotherapy-induced neutropaenia. We determined the safety and pharmacokinetics of MBL substitution in a phase II study in MBL-deficient children.Twelve MBL-deficient children with cancer (aged 0–12 years) received infusions of plasma-derived MBL once, or twice weekly during a chemotherapy-induced neutropaenic episode (range: 1–4 weeks). Four patients participated multiple times. Target levels of 1.0 μg/ml were considered therapeutic.In total, 65 MBL infusions were given. No MBL-related adverse reactions were observed, and the observed trough level was 1.06 μg/ml (range: 0.66–2.05 μg/ml). Pharmacokinetics were not related to age after correction for body weight. The half-life of MBL, for a child of 25 kg, was 36.4 h (range: 23.7–66.6 h). No anti-MBL antibodies were measured 4 weeks after each MBL course.Substitution therapy with MBL-SSI twice weekly was safe and resulted in trough levels considered protective.